All In Biotech

Drug Trial Radar · NCT05450887

Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis

A Randomized, Double-blind, Multicenter, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis

Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Sep 23, 2021

Primary completion

Mar 18, 2024

Study completion Apr 9, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. Conventional therapy with obecholic acid will improve liver function of patients with (primary biliary cholangitis)PBC. The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on safety in participants with PBC.

Conditions

  • Primary Biliary Cholangitis

Interventions

  • Obeticholic Acid Tablets(OCA)Drug

    Obeticholic Acid:Once a day (QD) by mouth (PO).

  • UDCADrug

    UDCA:13\~15 mg/kg/day

  • PlaceboDrug

    Placebo:Once a day (QD) by mouth (PO).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of PBC patients reaching the compound endpoint after 12 months of treatment (Compound endpoint: alkaline phosphatase (ALP) < 1.67× Upper Limit of Normal(ULN), and ALP decrease ≥ 15% from baseline, and total bilirubin ≤ ULN )Time frame: up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.